These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6097118)

  • 1. Cefmenoxime therapy in bacterial osteomyelitis.
    Sheftel TG; Cierny G; Lefrock JL; Mader JT
    Am J Med; 1984 Dec; 77(6A):17-20. PubMed ID: 6097118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of cefmenoxime in children.
    Tansino GF; Hammerschlag MR; Congeni BL; Cox PA; Doraiswamy B; duBouchet L
    Antimicrob Agents Chemother; 1985 Oct; 28(4):508-10. PubMed ID: 3865630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefmenoxime: clinical evaluation.
    Baker RL; Perkins RL
    Am J Med; 1984 Dec; 77(6A):53-9. PubMed ID: 6097126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of cefmenoxime versus cefoxitin in serious infections.
    Bechard DL; Hawkins SH; Sutherland SC
    Am J Med; 1984 Dec; 77(6A):13-6. PubMed ID: 6097117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with cefotaxime in the treatment of serious bone and joint infections.
    LeFrock JL; Carr BB
    Rev Infect Dis; 1982; 4 Suppl():S465-71. PubMed ID: 6294800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefmenoxime. Clinical, bacteriologic, and pharmacologic studies.
    LeFrock JL; Molavi A; McCloskey RV; Rolston K; Chandrasekar P; Henao L; Smith BR; Kannangara W; Schell RF; Carr BB
    Am J Med; 1984 Jul; 77(1):72-8. PubMed ID: 6331163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experimental and clinical studies of cefmenoxime in the field of obstetrics and gynecology].
    Takase Z; Noda K; Hayasaki M; Iwasa S; Motomura R; Yamabe T; Ichinohe K; Kutsuzawa T; Kaneko M; Domon H; Kodama M; Shimizu T; Mizoguchi H; Yorozu Y; Maki M; Chimura T; Matsuda S; Cho N; Fukunaga K; Kunii K; Wagatsuma T; Kaku R; Hogaki M; Ikawa M; Matsumoto Y; Fukuoka H; Honma T; Sanada K; Minakuchi H; Sumiyoshi Y; Hayashi S; Nakamura H; Goto T; Ihara Y; Hagiwara K; Tsuruta S; Yabuki A; Higashide K; Hasegawa Y; Ninomiya K; Okada H; Kanao M; Yasuda J; Takashima E; Ikeuchi M; Kobayashi Y; Haruta T; Hirabayashi K; Doko F; Watanabe K
    Jpn J Antibiot; 1982 Jun; 35(6):1585-609. PubMed ID: 6290708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of cefmenoxime in chronic complicated urinary tract infection].
    Ashiki A; Sudo Y; Suzuki T; Yamato K; Tsukui A; Hamada W; Kusumi Y
    Jpn J Antibiot; 1985 Jan; 38(1):49-61. PubMed ID: 3857363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefmenoxime therapy for gynecologic and obstetric infections.
    Rao B; Savage EW; Chuah SK; Bansal MB; Dhawan VK; Thadepalli H
    Obstet Gynecol; 1985 Sep; 66(3):377-83. PubMed ID: 3860790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefmenoxime: in vitro activity.
    Stamm JM
    Am J Med; 1984 Dec; 77(6A):1-3. PubMed ID: 6097114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone and joint infections caused by gram-positive bacteria: treatment with cefotaxime.
    LeFrock J; Mader J; Smith B; Carr B
    Infection; 1985; 13 Suppl 1():S50-5. PubMed ID: 4055056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical laboratory approach for estimating effective administrative dosage of cefmenoxime. Observation on the MICS and cefmenoxime disc susceptibility test].
    Uete T; Matsuo K
    Jpn J Antibiot; 1984 May; 37(5):791-801. PubMed ID: 6090721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of cefmenoxime in urinary tract and prostatic infections].
    Guibert J; Acar JF; Destree D; Bryskier A
    Pathol Biol (Paris); 1985 May; 33(5):330-4. PubMed ID: 3897962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical evaluation of cefmenoxime (CMX) for complicated urinary tract infection].
    Tsuchida S; Sasaki S; Takada H; Miyagata S; Sato S; Shimizu S; Sakamoto F; Kizu N
    Hinyokika Kiyo; 1985 Feb; 31(2):365-74. PubMed ID: 3859998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefmenoxime therapy of serious bacterial infections.
    Gombert ME; Glasser LA; Eng RH
    Antimicrob Agents Chemother; 1984 Apr; 25(4):510-2. PubMed ID: 6329082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefmenoxime efficacy, safety, and pharmacokinetics in critical care patients with nosocomial pneumonia.
    Schentag JJ; Reitberg DP; Cumbo TJ
    Am J Med; 1984 Dec; 77(6A):34-42. PubMed ID: 6097122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical results and concentrations of cefmenoxime in serum, amniotic fluid, mother's milk, and umbilical cord.
    Weissenbacher ER; Adams D; Gutschow K; Peters-Welte C; Luehr HG
    Am J Med; 1984 Dec; 77(6A):11-2. PubMed ID: 6097116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro bacteriostatic activity of cefmenoxime (SCE 1365), cefotaxime and moxalactam].
    Husson MO; Bryskier A; Izard D; Leclerc H
    Pathol Biol (Paris); 1983 May; 31(5):347-50. PubMed ID: 6312395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory evaluation of cefmenoxime: a new cephalosporin. In vitro and in vivo antibacterial activities and pharmacokinetic properties.
    Matsumoto K; Nagatake T; Uzuka Y; Harada T; Rikitomi N
    Chemotherapy; 1983; 29(2):80-8. PubMed ID: 6301776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefotaxime therapy for patients with osteomyelitis and septic arthritis.
    Mader JT; LeFrock JL; Hyams KC; Molavi A; Reinarz JA
    Rev Infect Dis; 1982; 4 Suppl():S472-80. PubMed ID: 6294801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.